Lansoprazole and carbonic anhydrase IX inhibitors sinergize against human melanoma cells

References

• Raghunand N, He X, van Sluis R, et al. Enhancement of chemotherapy by manipulation of tumour pH. Br J Cancer 1999;80:1005–11
   PubMed Web of Science ®Google Scholar
• Raghunand N, Martinez-Zaguilan R, Wright SH, Gillies RJ. pH and drug resistance. II. Turnover of acidic vesicles and resistance to weakly basic chemotherapeutic drugs. Biochem Pharmacol 1999;57:1047–58
   PubMed Web of Science ®Google Scholar
• Altan N, Chen Y, Schindler M, Sanford SM. Defective acidification in human breast tumor cells and implications for chemotherapy. J Exp Med 1998;187:1583–98
   PubMed Web of Science ®Google Scholar
• Ouar Z, Lacave R, Bens M, Vandewalle A. Mechanisms of altered sequestration and efflux of chemotherapeutic drugs by multidrug resistant cells. Cell Biol Toxicol 1999;15:91–100
   PubMed Web of Science ®Google Scholar
• Larsen AK, Escargueil AE, Skladanowski A. Resistance mechanisms associated with altered intracellular distribution of anticancer agents. Pharmacol Ther 2000;85:217–29
   PubMed Web of Science ®Google Scholar
• Federici C, Petrucci F, Caimi S, et al. Exosome release and low pH belong to a framework of resistance of human melanoma cells to cisplatin. PLoS One 2014;9:e88193
   PubMed Web of Science ®Google Scholar
• Izumi H, Torigoe T, Ishiguchu H, et al. Cellular pH regulators: potentially promising molecular targets for cancer chemotherapy. Cancer Treat Rev 2003;29:541–9
   PubMed Web of Science ®Google Scholar
• Taylor S, Spugnini EP, Assaraf YG, et al. Microenvironment acidity as a major determinant of tumor chemoresistance: proton pump inhibitors (PPIs) as a novel therapeutic approach. Drug Resist Updat 2015;23:69–78
   PubMed Web of Science ®Google Scholar
• Spugnini EP, Sonveaux P, Stock C, et al. Proton channels and exchangers in cancer. Biochim Biophys Acta 2015;1848:2715–26
   PubMed Web of Science ®Google Scholar
• De Milito A, Fais S. Tumor acidity, chemoresistance and proton pump inhibitors. Future Oncol 2005;1:779–86
   PubMedGoogle Scholar
• Nishi T, Forgac M. The vacuolar (H+)-ATPases-nature's most versatile proton pumps. Nat Rev Mol Cell Biol 2002;3:94–103
   PubMed Web of Science ®Google Scholar
• Martinez-Zaguilan R, Lynch RM, Martinez GM, Gillies RJ. Vacuolar-type H(þ)-ATPases are functionally expressed in plasma membranes of human tumor cells. Am J Physiol 1993;265:C1015–29
   PubMed Web of Science ®Google Scholar
• Sennoune SR, Bakunts K, Martinez GM, et al. Vacuolar H-ATPase in human breast cancer cells with distinct metastatic potential: distribution and functional activity. Am J Physiol Cell Physiol 2004;286:89–98
   Web of Science ®Google Scholar
• Mattsson JP, Vaananen K, Wallmark B, Lorentzon P. Omeprazole and bafilomycin, 2 proton pump inhibitors: differentiation of their effects on gastric, kidney and bone H+-translocating ATPases. Biochim Biophys Acta 1991;1065:261–8
   PubMed Web of Science ®Google Scholar
• Moriyama Y, Patel V, Ueda I, Futai M. Evidence for a common binding site for omeprazole and N-ethylmaleimide in subunit A of chromaffin granule vacuolar-type H(+)-ATPase. Biochem Biophys Res Commun 1993;196:699–706
   PubMed Web of Science ®Google Scholar
• Horn J. The proton-pump inhibitors: similarities and differences. Clin Ther 2000;22:266–80
   PubMed Web of Science ®Google Scholar
• Wallmark B, Larsson H, Humble L. The relationship between gastric acid secretion and gastric H+, K+-ATPase activity. J Biol Chem 1985;260:13681–4
   PubMed Web of Science ®Google Scholar
• Puscas I, Coltau M, Baican M, Domuta G. Omeprazole has a dual mechanism of action: it inhibits both H+, K+-ATPase and gastric mucosa carbonic anhydrase enzyme in humans (in vitro and in vivo experiments). J Pharmacol Exp Ther 1999;290:530–4
   PubMed Web of Science ®Google Scholar
• Mizunashi K, Furukawa Y, Katano K, Abe K. Effect of omeprazole, an inhibitor of H+, K(+)-ATPase, on bone resorption in humans. Calcif Tissue Int 1993;53:21–5
   PubMed Web of Science ®Google Scholar
• Olbe L, Carlsson E, Lindberg P. A proton-pump inhibitor expedition: the case histories of omeprazole and esomeprazole. Nat Rev Drug Discov 2003;2:132–9
   PubMed Web of Science ®Google Scholar
• Fais S. Proton pump inhibitor-induced tumour cell death by inhibition of a detoxification mechanism. J Intern Med 2010;267:515–25
   PubMed Web of Science ®Google Scholar
• Luciani F, Spada M, De Milito A, et al. Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs. J Natl Cancer Inst 2004;96:1702–13
   PubMed Web of Science ®Google Scholar
• Chen M, Zou X, Luo H, et al. Effects and mechanisms of proton pump inhibitors as a novel chemosensitizer on human gastric adeno carcinoma (SGC7901) cells. Cell Biol Int 2009;33:1008–19
   PubMed Web of Science ®Google Scholar
• Chen M, Huang SL, Zhang XQ, et al. Reversal effects of pantoprazole on multidrug resistance in human gastric adenocarcinoma cells by down-regulating the V-ATPases/mTOR/HIF-1α/P-gp and MRP1 signaling pathway in vitro and in vivo. J Cell Biochem 2012;113:2474–87
   PubMed Web of Science ®Google Scholar
• Udelnow A, Kreyes A, Ellinger S, et al. Omeprazole inhibits proliferation and modulates autophagy in pancreatic cancer cells. PLoS One 2011;6:e20143
   PubMed Web of Science ®Google Scholar
• Wang BY, Zhang J, Wang JL, et al. Intermittent high dose proton pump inhibitor enhances the antitumor effects of chemotherapy in metastatic breast cancer. J Exp Clin Cancer Res 2015;34:2–12
   PubMed Web of Science ®Google Scholar
• Azzarito T, Venturi G, Cesolini A, Fais S. Lansoprazole induces sensitivity to suboptimal doses of paclitaxel in human melanoma. Cancer Lett 2015;356:697–703
   PubMed Web of Science ®Google Scholar
• You H, Jin J, Shu H, et al. Small interfering RNA targeting the subunit ATP6L of proton pump V-ATPase overcomes chemoresistance of breast cancer cells. Cancer Lett 2009;18:110–19
   Web of Science ®Google Scholar
• De Milito A, Iessi E, Logozzi M, et al. Proton pump inhibitors induce apoptosis of human B-cell tumors through a caspase-independent mechanism involving reactive oxygen species. Cancer Res 2007;67:5408–17
   PubMed Web of Science ®Google Scholar
• De Milito A, Canese R, Marino ML, et al. pH dependent antitumor activity of proton pump inhibitors against human melanoma is mediated by inhibition of tumor acidity. Int J Cancer 2010;127:207–19
   PubMed Web of Science ®Google Scholar
• Lindner K, Borchardt C, Schopp M, et al. Proton pump inhibitors (PPIs) impact on tumour cell survival, metastatic potential and chemotherapy resistance, and affect expression of resistance relevant miRNAs in esophageal cancer. J Exp Clin Cancer Res 2014;33:73–84
   PubMed Web of Science ®Google Scholar
• Yeo M, Kim DK, Kim YB, et al. Selective induction of apoptosis with proton pump inhibitor in gastric cancer cells. Clin Cancer Res 2004;10:8687–96
   PubMed Web of Science ®Google Scholar
• Avnet S, Di Pompo G, Lemma S, et al. V-ATPase is a candidate therapeutic target for Ewing sarcoma. Biochim Biophys Acta 2013;1832:1105–16
   PubMed Web of Science ®Google Scholar
• Ferrari S, Perut F, Fagioli F, et al. Proton pump inhibitor chemosensitization in human osteosarcoma: from the bench to the patients' bed. J Transl Med 2013;11:268–74
   PubMed Web of Science ®Google Scholar
• Perut F, Avnet S, Fotia C, et al. V-ATPase as an effective therapeutic target for sarcomas. Exp Cell Res 2013;320:21–32
   Web of Science ®Google Scholar
• Spugnini EP, Baldi A, Buglioni S, et al. Lansoprazole as a rescue agent in chemoresistant tumors: a phase I/II study in companion animals with spontaneously occurring tumors. J Transl Med 2011;9:221–32
   PubMed Web of Science ®Google Scholar
• Spugnini EP, Buglioni S, Carocci F, et al. High dose lansoprazole combined with metronomic chemotherapy: a phase I/II study in companion animals with spontaneously occurring tumors. J Transl Med 2014;12:225–35
   PubMed Web of Science ®Google Scholar
• Lugini L, Federici C, Borghi M, et al. Enzyme proton pump inhibitors while belonging to the same family of generic drugs show different anti-tumor effect. J Enzyme Inhib Med Chem 2015;28:1–8
   Web of Science ®Google Scholar
• Thiry A, Supuran CT, Masereel JM, Dogné JM. Recent developments of carbonic anhydrase inhibitors as potential anticancer drugs. J Med Chem 2008;51:3051–6
   PubMed Web of Science ®Google Scholar
• Ekinci D, Cavdar H, Durdagi S, et al. Structure-activity relationships for the interaction of 5,10-dihydroindeno[1,2-b]indole derivatives with human and bovine carbonic anhydrase isoforms I, II, III, IV and VI. Eur J Med Chem 2012;49:68–73
   PubMed Web of Science ®Google Scholar
• Hilvo M, Baranauskiene L, Salzano AM, et al. Biochemical characterization of CA IX, one of the most active carbonic anhydrase isozymes. J Biol Chem 2008;283:27799–809
   PubMed Web of Science ®Google Scholar
• Ekinci D, Cavdar H, Talaz O, et al. NO-releasing esters show carbonic anhydrase inhibitory action against human isoforms I and II. Bioorg Med Chem 2010;18:3559–63
   PubMed Web of Science ®Google Scholar
• Innocenti A, Vullo D, Scozzafava A, Supuran CT. Carbonic anhydrase inhibitors: inhibition of mammalian isoforms I-XIV with a series of substituted phenols including paracetamol and salicylic acid. Bioorg Med Chem Lett 2008;18:1583–7
   PubMed Web of Science ®Google Scholar
• Akin Kazancioglu E, Guney M, Senturk M, Supuran CT. Simple methanesulfonates are hydrolyzed by the sulfatase carbonic anhydrase activity. J Enzyme Inhib Med Chem 2012;27:880–5
   PubMed Web of Science ®Google Scholar
• Ekinci D, Senturk M, Kufrevioglu OI. Salicylic acid derivatives: synthesis, features and usage as therapeutic tools. Expert Opin Ther Pat 2011;21:1831–41
   PubMed Web of Science ®Google Scholar
• Khalifah RG. The carbon dioxide hydration activity of carbonic anhydrase I. Stop-flow kinetic studies on the native human isoenzymes B and C. J Biol Chem 1971;246:2561–73
   PubMed Web of Science ®Google Scholar
• Rofstad EK, Mathiesen B, Kindem K, Galappathi K. Acidic extracellular pH promotes experimental metastasis of human melanoma cells in athymic nude mice. Cancer Res 2006;66:6699–707
   PubMed Web of Science ®Google Scholar
• Fais S, De Milito A, You H, Qin W. Targeting vacuolar H+-ATPases as a new strategy against cancer. Cancer Res 2007;67:10627–30
   PubMed Web of Science ®Google Scholar
• Fais S, Venturi G, Gatenby B. Microenvironmental acidosis in carcinogenesis and metastases: new strategies in prevention and therapy. Cancer Metastasis Rev 2014;33:1095–108
   PubMed Web of Science ®Google Scholar
• Fan S, Niu Y, Tan N, et al. LASS2 enhances chemosensitivity of breast cancer by counteracting acidic tumor microenvironment through inhibiting activity of V-ATPase proton pump. Oncogene 2013;28:1682–90
   Web of Science ®Google Scholar
• Supuran CT, Scozzafava A. Applications of carbonic anhydrase inhibitors and activators in therapy. Expert Opin Ther Patents 2002;12:217–42
   Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov 2008;7:168–81
   PubMed Web of Science ®Google Scholar
• Ward C, Meehan J, Mullen P, et al. Evaluation of carbonic anhydrase IX as a therapeutic target for inhibition of breast cancer invasion and metastasis using a series of in vitro breast cancer models. Oncotarget 2015;6:24856–70
   PubMed Web of Science ®Google Scholar
• Cianchi F, Vinci MC, Supuran CT, et al. Selective inhibition of carbonic anhydrase IX decreases cell proliferation and induces ceramide-mediated apoptosis in human cancer cells. J Pharmacol Exp Ther 2010;334:710–19
   PubMed Web of Science ®Google Scholar
• Monti SM, Supuran CT, De Simone G. Anticancer carbonic anhydrase inhibitors: a patent review (2008-2013). Expert Opin Ther Pat 2013;23:737–49
   PubMed Web of Science ®Google Scholar
• Sharma A, Tiwari M, Supuran CT. Novel coumarins and benzocoumarins acting as isoform-selective inhibitors against the tumor-associated carbonic anhydrase IX. J Enzyme Inhib Med Chem 2014;29:292–6
   PubMed Web of Science ®Google Scholar
• Pan J, Lau J, Mesak F, et al. Synthesis and evaluation of 18F-labeled carbonic anhydrase IX inhibitors for imaging with positron emission tomography. J Enzyme Inhib Med Chem 2014;2:249–55
   Web of Science ®Google Scholar
• Supuran CT. Structure-based drug discovery of carbonic anhydrase inhibitors. J Enzyme Inhib Med Chem 2012;6:759–72
   Web of Science ®Google Scholar
• Nocentini A, Ceruso M, Carta F, Supuran CT. 7-Aryl-triazolyl-substituted sulfocoumarins are potent, selective inhibitors of the tumor-associated carbonic anhydrase IX and XII. J Enzyme Inhib Med Chem 2015. [Epub ahead of print] doi: 10.3109/14756366.2015.1115401
   PubMed Web of Science ®Google Scholar
• Swietach P, Vaughan-Jones RD, Harris AL. Regulation of tumor pH and the role of carbonic anhydrase 9. Cancer Metastasis Rev 2007;26:299–310
   PubMed Web of Science ®Google Scholar
• Swietach P, Patiar S, Supuran CT, et al. The role of carbonic anhydrase 9 in regulating extracellular and intracellular pH in three-dimensional tumor cell growths. J Biol Chem 2009;284:20299–310
   PubMed Web of Science ®Google Scholar
• Neri D, Supuran CT. Interfering with pH regulation in tumours as a therapeutic strategy. Nat Rev Drug Discov 2011;10:767–77
   PubMed Web of Science ®Google Scholar
• Winum J-Y, Carta F, Ward C, et al. Ureido-substituted sulfamates show potent carbonic anhydrase IX inhibitory and antiproliferative activities against breast cancer cell lines. Bioorg Med Chem Lett 2012;22:4681–5
   PubMed Web of Science ®Google Scholar
• Huber V, De Milito A, Harguindey S, et al. Proton dynamics in cancer. J Transl Med 2010;8:57–60
   PubMed Web of Science ®Google Scholar